Formulation and Evaluation of Swellable Oral Thin Film of Metoclopramide Hydrochloride

Marzia Alam, Farhana Tasneem and Md. Saiful Islam Pathan

Department of Pharmacy, State University of Bangladesh, Dhanmondi, Dhaka-1209, Bangladesh

Abstract
Traditionally metoclopramide hydrochloride is used as an antiemetic in migraine & cancer patients and in controlling post-operative nausea and vomiting. The main aim of this study was to develop a swellable oral thin film for the treatment of the mentioned pathological conditions. This swellable thin film formulation is specially designed for paediatric patients for oral administration, where it will swell up when exposed to saliva in the oral cavity and will be easily swallowed by the patient, without the need for water. Nine formulations of swellable oral thin film of metoclopramide hydrochloride such as F1 to F9 were prepared by solvent casting method. The drug–Povidone K90 ratio were 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8 and 1:9, respectively. Various physicochemical evaluations including weight variation, thickness, folding endurance, in vitro dissolution studies, content uniformity, FTIR, Trinocular microscopic imaging and swelling property of film were conducted. It was observed that thickness and weight of film was directly proportional to the total solid content of the film (F1 showed the lowest thickness and weight and F9 showed the highest). All the batches revealed content uniformity between 98.0% to 101.0% and cumulative drug release between 94.8% and 102.4%. Swelling behavior of film was inversely proportional to the quantity of Povidone K90 in the film. Formulation F9 showed the highest linear expansion co-efficient (L%) and percentage increase in weight due to swelling while F3 demonstrated the lowest corresponding to the quantity of Povidone K90. Quantity of glycerin and Povidone K90 affected the appearance and peeling of the films. F1, F2 and F3 had lowest quantity of glycerin and Povidone K90 and were least glossy and easier to peel out and F7, F8 and F9 with highest quantity of glycerin and Povidone K90 and were glossiest but hardest to peel out.

Key words: Formulation, Evaluation, Swellable Oral Thin Film, Metoclopramide Hydrochloride.

Introduction
Oral administration is the most popular route due to ease of ingestion, pain avoidance, versatility (to accommodate various types of drug candidates), and most importantly, patient compliance. In addition, solid oral delivery systems do not require sterile conditions and are, therefore, less expensive to manufacture. Several novel technologies for oral delivery have recently become available to address the physicochemical and pharmacokinetic characteristics of drugs, while improving patient compliance. The administration of medicinal products in patients depends principally on age, physical development and ability to coordinate but also to psychological development and understanding (Committee for medicinal and products for human use, 2006). The administration of medications to pediatric patients is difficult in many ways because the health care providers and parents face many challenges not experienced, or experienced to a lesser degree, than when medications are prescribed for and taken by adults. Firstly, less information is available about the use of most medications for pediatric patients. In fact, only about 20% of drugs marketed in the United States have labeling for pediatric use. Secondly, many drugs that are used for some pediatric patients are not in appropriate dosage forms for use by children. This includes even some medications approved for use in pediatric patients (Sagraves, 2006). A major concern is at what age children can safely swallow solid oral dosage forms such as tablets or capsules is not clearly defined. There resulted the need for diverse solid oral dosage forms for pediatric population. Oral thin films (Hideaki et al., 2008) are novel drug delivery systems especially suitable for both pediatric and geriatric patients who experience difficulties in swallowing traditional solid oral dosage forms (Committee for medicinal and products for human use, 2006). Difficulty in swallowing
(dysphasia) is common among all age groups, especially in elderly, and is also seen in swallowing conventional tablets and capsules. Dysphasia is associated with many medical conditions, including stroke, Parkinson’s disease, AIDS, thyroidectomy, head and neck radiation therapy, and other neurological disorders, including cerebral palsy. The most common complaint are tablet size, followed by surface, form and taste. The problem of swallowing tablets was more evident in geriatric and pediatric patients, as well as travelling patients who may not have ready access to water (Committee for medicinal and products for human use, 2006). USP (2012) defines films as "thin sheets that are placed in the oral cavity. They contain one or more layers. A layer may or may not contain a drug substance". Oral thin film is one sub-category of pharmaceutical film. Oral thin films are novel oral drug delivery system. These drug delivery systems are rapidly gaining interest in the pharmaceutical industry because they either dissolve or disintegrate generally within a minute without water or chewing. These systems offer superior clinical profiles with potential oromucosal absorption thus increasing the drug bioavailability with respect to other routes of oral administration.

Research and development in the oral drug delivery segment have to transition of dosage forms from simple conventional tablets/capsules to orally disintegrating tablet (ODT) to wafer to the recent development of oral films (ODF). A number of molecules can be incorporated into this delivery system. They may include cough/cold remedies (antitussives, expectorants), sore throat, erectile dysfunction drugs, antihistaminic, antiasthmatics, gastrointestinal drugs, nausea, pain and CNS (e.g. antiparkinsons disease), caffeine strips, snoring aid, multivitamins, sleeping aid etc. In the present study, a traditional antiemetic drug metoclopramide hydrochloride was chosen as the model drug. Metoclopramide hydrochloride is a dopaminergic blocker of BCS class III drug. It promotes gut motility by inhibiting presynaptic and postsynaptic D2 receptors as well as presynaptic 5-HT₄ receptors. Metoclopramide also produces antiemetic effects by inhibition of D₂ and 5-HT₄ receptors in the CTZ (Chemoreceptor trigger zone).

Materials and Methods

Metoclopramide hydrochloride was obtained as a gift sample from Opsonin Pharmaceuticals Ltd., Dhaka, Bangladesh. Povidone K90 (Kollidon K90) was obtained from BASF, Germany. Polyvinyl alcohol (98-99% hydroxylation) and Carbopol 971P, Calcium chloride (anhydrous), Citric acid (anhydrous) and Titanium dioxide was purchased from Merck, India. Sucrose was obtained from Drug International Ltd., Dhaka, Bangladesh. Other ingredients used were of analytical grade.

Table 1. Formulation of swellable oral thin film of metoclopramide hydrochloride.

<table>
<thead>
<tr>
<th>Ingredients (mg)</th>
<th>F₁</th>
<th>F₂</th>
<th>F₃</th>
<th>F₄</th>
<th>F₅</th>
<th>F₆</th>
<th>F₇</th>
<th>F₈</th>
<th>F₉</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metoclopramide hydrochloride</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Povidone K90</td>
<td>5</td>
<td>10</td>
<td>15</td>
<td>20</td>
<td>25</td>
<td>30</td>
<td>35</td>
<td>40</td>
<td>45</td>
</tr>
<tr>
<td>Glycerin</td>
<td>0.25</td>
<td>0.25</td>
<td>0.25</td>
<td>0.40</td>
<td>0.40</td>
<td>0.40</td>
<td>0.55</td>
<td>0.55</td>
<td>0.55</td>
</tr>
<tr>
<td>Sucrose</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Citric acid (anhydrous)</td>
<td>0.2</td>
<td>0.2</td>
<td>0.2</td>
<td>0.2</td>
<td>0.2</td>
<td>0.2</td>
<td>0.2</td>
<td>0.2</td>
<td>0.2</td>
</tr>
<tr>
<td>Titanium dioxide</td>
<td>0.6</td>
<td>0.6</td>
<td>0.6</td>
<td>0.6</td>
<td>0.6</td>
<td>0.6</td>
<td>0.6</td>
<td>0.6</td>
<td>0.6</td>
</tr>
<tr>
<td>Distilled water</td>
<td>173.3</td>
<td>173.3</td>
<td>173.3</td>
<td>173.3</td>
<td>173.3</td>
<td>173.3</td>
<td>173.3</td>
<td>173.3</td>
<td>173.3</td>
</tr>
<tr>
<td>Polyvinyl alcohol</td>
<td>9.7</td>
<td>9.7</td>
<td>9.7</td>
<td>9.7</td>
<td>9.7</td>
<td>9.7</td>
<td>9.7</td>
<td>9.7</td>
<td>9.7</td>
</tr>
<tr>
<td>Carbopol 971P</td>
<td>3.2</td>
<td>3.2</td>
<td>3.2</td>
<td>3.2</td>
<td>3.2</td>
<td>3.2</td>
<td>3.2</td>
<td>3.2</td>
<td>3.2</td>
</tr>
<tr>
<td>Glycerin</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
</tr>
<tr>
<td>Calcium chloride (anhydrous)</td>
<td>0.1</td>
<td>0.1</td>
<td>0.1</td>
<td>0.1</td>
<td>0.1</td>
<td>0.1</td>
<td>0.1</td>
<td>0.1</td>
<td>0.1</td>
</tr>
<tr>
<td>Sucrose</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
</tr>
<tr>
<td>Distilled water</td>
<td>534.00</td>
<td>534.00</td>
<td>534.00</td>
<td>534.00</td>
<td>534.00</td>
<td>534.00</td>
<td>534.00</td>
<td>534.00</td>
<td>534.00</td>
</tr>
</tbody>
</table>

Method of preparation of swellable oral thin film:The drug layer was prepared by dissolving citric acid (anhydrous) in distilled water taken in a beaker. Titanium dioxide was added to the solution and homogenized for 5
minutes. Povidone K90 was added gradually and mixed using homogenizer. Glycerin and sucralose was added and homogenized for 5 minutes. Finally, required quantity of metoclopramide HCl was added and mixed well for 15 minutes to dissolve completely.

To prepare the gelling layer accurately weighed quantity of CaCl\(_2\) was dissolved in distilled water. To this solution carbopol 971P was gradually added and homogenized to dissolve completely to prepare the gelling solution. Polyvinyl alcohol was added and heated to dissolve. Lastly glycerin and sucralose were added to this and homogenized well. The order of material addition and dissolution was strictly maintained to obtain a gelling solution of consistent quality. The solution was kept aside until the bubbles were disappeared. Then required quantity of gelling layer solution was casted onto glass plate very carefully avoiding formation of bubbles and ensuring uniform distribution.

The casted plates were oven dried at 55-60°C for 3.5-4 hours or until drying. Two plates were casted for each swellable film. One is the bottom gelling layer and another is the top gelling layer. The required quantity of drug layer was casted onto the bottom gelling layer carefully and uniformly, avoiding formation of bubbles. The drug layer was dried in hot air oven at 50-55°C for about 120 minutes and the drug layer was removed from the oven when stickiness remained.

To prepare the swellable oral thin film, the top gelling layer was removed from the plate very carefully to avoid any damage to the film. The top gelling layer was then placed carefully on the drug layer. This swellable film was dried in hot air oven at 50-55°C until LOD was met but the film did not become crispy. The dried film (Figure 1) was then removed from the plate and cut into the desired size and shape.

**Morphological properties of film:** Properties such as homogeneity, color, transparency and surface of the oral films were evaluated by visual inspection (Raju et al., 2011; Prabhakara et al., 2008).

**Mass of swellable oral thin film of metoclopramide HCl:** Mass of individual films was studied by taking randomly selected films and individually weighting 10 thin films and calculating the average mass. The standard deviation was calculated. The individual mass should not deviate significantly from the average weight.

**Thickness of film:** The thickness of the film sample was measured using a micrometer (Digimatic Micrometer, Mitutoyo, Tokyo, Japan) at five locations (centre and 4 corners). The mean thickness and relative standard deviation was calculated.

**Folding endurance:** The folding endurance is expressed as the number of folds either to break a specimen or to develop visible cracks. It was determined by repeatedly folding a patch of 20×20 mm size at the same place until it broke (Narsimha et al., 1997). Three films of each formulation of size (10 mm × 20 mm) were cut by using a sharp blade. Folding endurance was determined by repeatedly folding a small strip of film at the same place until it broke. The number of times the film can be folded at the same place without breaking gave the value of folding endurance. The mean value of three readings and standard deviation were then calculated.

**Surface pH study:** The surface pH of films is determined to investigate the possible side effect because of change in pH in vivo, since an acidic or alkaline pH may cause irritation to buccal mucosa. The film to be tested was placed in a Petri dish and was moistened with 0.5 mL of distilled water and kept for 30 s. The pH was noted after bringing the pH paper in contact with the surface of the formulation and allowing equilibrating for 1 min (Kumar et al., 2005).
Measurement of swelling property of the film

**Linear expansion co-efficient of film:** The film (1 x 1 cm$^2$) was placed in a petridish and immersed in 10 ml of distilled water. Specimens were taken at 30, 40, 60, 80, 100, 120, 140, 160 and 180 seconds and the size of the side length was measured. The linear expansion coefficient (L) was defined as 

$$L(\%) = \left(\frac{L_1 - L_0}{L_0}\right) \times 100$$

where $L_1$= side length of the film after immersion and $L_0$= the side length of the film before immersion (Ahmed et al., 2010).

**Amount absorbed in distilled water:** The gelating layer (1 cm x 1 cm square) was weighed ($W_1$) and put in a pre-weighed cover slip. It was kept in a petridish and 10 ml of distilled water was added. After every 10 seconds, the cover slip was removed and weighed up to 3 minutes. The increase in weight due to absorption of water and swelling of film (Okabe et al., 2008) was defined as

$$W(g/g) = \frac{(W_2 - W_1 - W_3)}{W_1}$$

where, $W_1$= Initial weight of the film, $W_2$= Weight of the film after absorption of water, $W_3$= Weight of the cover slip.

**In vitro dissolution test:** The in vitro drug release study was carried out using USP 23 type-I basket type dissolution test apparatus in 900 ml of phosphate buffer (pH 6.8) at 50 RPM. The temperature of the medium was set at 37± 2°C and number of films per evaluation was three. Aliquots of 5 ml were withdrawn and the sample volume replaced with an equal volume of fresh dissolution medium. The samples were analysed spectrophotometrically at 273 nm. The samples were weighed and taken separately in 100 ml volumetric flask and filled with 50 ml phosphate buffer pH 6.8 and sonicated for 15 minutes to dissolve completely. The solution was made up to the mark and filtered using Whatman filter paper. The sample solution was diluted 25 times and drug content was determined spectrophotometrically at 273 nm.

**FTIR studies of metoclopramide hydrochloride swellable oral thin film:** Appropriate quantity of KBr and sample (in the ratio 200:0.1) were mixed by grinding in an agate mortar. Pellets were made with 100 mg mixture. FT-IR spectra were recorded with FT-IR 8400S Shimadzu spectrophotometer in the range 4000-400 cm$^{-1}$ (Resolution: 2 cm$^{-1}$ and number of scans was 30 times) (Shahriar et al., 2013; Sultana et al. 2013).

**Trinocular microscopic imaging of metoclopramide hydrochloride swellable oral thin film:** Trinocular microscopic image of swellable oral thin film of metoclopramide hydrochloride was taken and evaluated. The surface of the film and distribution of polymer and drug within the film was examined.

**Results and Discussion**

Swellable oral thin films of metoclopramide hydrochloride were prepared by solvent casting method using different povidone K 90 concentrations in the drug layer. Glycerin was used as the plasticizer. Titanium dioxide was used as an opacifying/tinting agent; citric acid (anhydrous) was used as saliva stimulating agent and sucralose as the sweetening agent. The gelling layer composition was kept constant for all the formulations from F1 to F9 and contained polyvinyl alcohol as the gel-forming polymer and Carbopol 971P as the swelling agent. Calcium chloride was used as complexing agent, which formed complex with the carboxyl group of polyvinyl alcohol. The solvent system used was water.
Mass of film: The mass of the film formulations varied proportionally with the solid content of the film. F1 having the lowest solid content (26.05 mg) has the lowest mass and F9 having the highest solid content (66.35 mg) has the highest weight. The formulated swellable oral thin films had mass variation within the range of pharmacoeial specifications. Figure 2 shows the comparative values of mass of film using different quantities of polymer in drug layer.

![Mass of film](image1)

Thickness of film: The increase in thickness was directly proportional to the solid content of the film formulation. F1 having the lowest solid content (26.05 mg) has the lowest thickness and F9 having the highest solid content (66.35 mg) has the highest thickness. Figure 3 shows the comparative values of thickness of film using different quantities of polymer in drug layer.

![Thickness of film](image2)

Folding endurance: The folding endurance of the formulated films was above 500 times of folding which indicates satisfactory mechanical strength.

Swelling behavior of film: The swelling behaviour of the film was a function of quantity of povidone K 90 in the drug layer. An inverse relationship was found to exist between linear expansion (percentage L) and quantity of...
Povidone K90 polymer. F_1 had the highest F_1 had the highest percentage of 50.167% and F_9 had the lowest L% of 5.00%. The mean values of % mass increase for F_1 is 740.80%, F_2 is 441.50%, F_3 is 570.60%, F_4 is 269.40%, F_5 is 230.00%, F_6 is 317.40%, F_7 is 271.62%, F_8 is 294.4% and F_9 is 224.4%. The amount of water absorbed by film was also inversely proportional to quantity of Povidone K90 polymer. Figure 4 shows the swelling behaviour of metoclopramide swellable oral thin film at different times (1, 2, 3, 4, 5 and 6 minutes). Figures 5 and 6 show the linear expansion co-efficient of film, linear expansion co-efficient of gelling layer and the amount of water absorbed by film respectively. Tables 2, 3 and 4 show the comparative data of linear expansion coefficient of formulations F_1 to F_9, linear expansion co-efficient values of gelling layer and amount of water absorbed by film respectively.

In vitro dissolution: All the film formulations showed release pattern similar immediate release dosage forms. In first 5 minutes, the formulations show 11.0% to 24.00% release. No formulation showed percentage cumulative release more than 84% in the first 15 minutes. However, 100% drug release was observed within 20 minutes for all the formulations (Figure 7). Table 5 shows the cumulative drug release at definite time intervals.

Swelling property of the gelling layer: The following table shows the linear expansion co-efficient (L %) of the gelling layer. It appears from the data that the linear expansion of gelling layer alone is higher than the film as a whole. The highest linear expansion was observed in F_1 (50.167%), but the gelling layer showed a linear expansion co-efficient of 67.00 %

Content uniformity of film: All the formulated batches had percent drug content between 98.0% to 101.0% (Figure 8). The standard deviation values of all batches were below 1.00, which indicates content uniformity of the film formulations.

FT-IR studies
FT-IR studies of film showed (Figures 9 and 10) slight changes in peaks compared to the metoclopramide hydrochloride standard, which needs further study.
Table 2. Linear expansion co-efficient of formulations F1 to F9.

<table>
<thead>
<tr>
<th>Sl. No.</th>
<th>F Code</th>
<th>Measure of side length (mm) with time (sec)</th>
<th>Linear expansion co-efficient (L%)</th>
<th>Mean value ± S.D. n=3</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>030 40 60 80 100 120 140 180</td>
<td></td>
<td></td>
</tr>
<tr>
<td>01</td>
<td>F1</td>
<td>10 11 13 14 13.5 14 14.5 14.5 15</td>
<td>50</td>
<td>50.167±0.289</td>
</tr>
<tr>
<td>02</td>
<td>F2</td>
<td>10 10 13 13 13 14 14.05 14.25 14.5</td>
<td>45</td>
<td>45.00±0.00</td>
</tr>
<tr>
<td>03</td>
<td>F3</td>
<td>10 10.5 13 13 13.5 13.75 14 14 14</td>
<td>40</td>
<td>40.167±0.289</td>
</tr>
<tr>
<td>04</td>
<td>F4</td>
<td>10 10 10 10 10 12 12.5 13.05 13.05</td>
<td>30.5</td>
<td>30.167±0.289</td>
</tr>
<tr>
<td>05</td>
<td>F5</td>
<td>10 10.5 11 12 12 12.5 12.5 12.5 12.5</td>
<td>25</td>
<td>25.00±0.00</td>
</tr>
<tr>
<td>06</td>
<td>F6</td>
<td>10 10 11 11 11 11.05 11.05 11.05 12</td>
<td>20</td>
<td>20.167±0.289</td>
</tr>
<tr>
<td>07</td>
<td>F7</td>
<td>10 10 10 10 11 11 10.5 10.5 10.5 10.5</td>
<td>20</td>
<td>20.333±0.289</td>
</tr>
<tr>
<td>08</td>
<td>F8</td>
<td>10 10 10 10 10 12 12 12 12 12 12 12</td>
<td>20</td>
<td>20.667±0.289</td>
</tr>
<tr>
<td>09</td>
<td>F9</td>
<td>10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10</td>
<td>5</td>
<td>5.00±0.00</td>
</tr>
</tbody>
</table>

Figure 5. Linear expansion co-efficient of formulations F1 to F9.
### Table 3. Linear expansion co-efficient of gelling layer.

<table>
<thead>
<tr>
<th>SL. No.</th>
<th>F Code</th>
<th>Measure of side length (mm) with time (sec)</th>
<th>Linear expansion co-efficient (L %)</th>
<th>Mean value ± S.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>0  30  40  60  80  100  120  140  180</td>
<td></td>
<td></td>
</tr>
<tr>
<td>01</td>
<td>Gelling layer</td>
<td>10  12  12.75  13  14  15  15  15  16.60</td>
<td>66.00</td>
<td>67.00±0.866</td>
</tr>
<tr>
<td></td>
<td></td>
<td>10  12  12.5  13  14  15  15  15  16.75</td>
<td>67.50</td>
<td></td>
</tr>
</tbody>
</table>

### Table 4. Amount absorbed in distilled water by film

<table>
<thead>
<tr>
<th>SL. No.</th>
<th>F Code</th>
<th>Increase in weight (mg) with time (sec)</th>
<th>% increase (wt.)</th>
<th>Mean value ± S.D.</th>
<th>Mean value ± S.D. n=3</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>0  10  20  30  40  50  60  70  80  90  100  110  120</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>01 F1</td>
<td>12</td>
<td>160.5 164 183.3 185.2 185.2 200.5 200.5 213.7 216.2 216.2 216.2</td>
<td>74.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>12.2</td>
<td>163.7 166 183 185 181 210 211 211 215.6 217.8 217.8</td>
<td>740.98</td>
<td>740.77 740.8±0.69</td>
<td></td>
</tr>
<tr>
<td></td>
<td>12.1</td>
<td>170.2 171 189.9 191.7 192.2 192.8 192.8 201.1 220.7 222 222</td>
<td>741.32</td>
<td></td>
<td></td>
</tr>
<tr>
<td>02 F2</td>
<td>17.3</td>
<td>148.8 148 161.1 183.3 193 197.2 205.8 210.9 210.9 210.9 210.9</td>
<td>441.04</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>18</td>
<td>153.3 155 153 165.4 190.1 195.7 200.1 210.9 213.1 215.2 216.5</td>
<td>441.67</td>
<td>441.47 441.5±0.38</td>
<td></td>
</tr>
<tr>
<td></td>
<td>17.5</td>
<td>147.7 148 150.1 162.1 187.2 195.7 209.3 213.8 211.1 211.1 211.1</td>
<td>441.71</td>
<td></td>
<td></td>
</tr>
<tr>
<td>03 F3</td>
<td>19.7</td>
<td>219.9 229 243.4 250.7 261.5 238 239.7 242.4 250.8 250.8 250.8</td>
<td>570.56</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>20</td>
<td>152.7 179 197.7 203.4 207.3 210.5 226.6 240.5 252.1 252.1 252.1</td>
<td>571.00</td>
<td>570.57 570.6±0.43</td>
<td></td>
</tr>
<tr>
<td></td>
<td>20.1</td>
<td>150.1 168 180.1 189.7 203.4 210.8 230.4 232.5 250.2 250.2 250.2</td>
<td>570.15</td>
<td></td>
<td></td>
</tr>
<tr>
<td>04 F4</td>
<td>30.4</td>
<td>151.1 155 170.1 173.1 190.2 210.1 228.6 230.1 230.1 230.1 230.1</td>
<td>269.41</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>31</td>
<td>253.1 157 173.1 175.1 193.2 220.2 230.3 233.6 233.6 233.9 233.9</td>
<td>269.68</td>
<td>269.42 269.4±0.25</td>
<td></td>
</tr>
<tr>
<td></td>
<td>30.5</td>
<td>150 157 175.2 190.1 189.1 217.7 228 228.9 231.1 227.2 227.2</td>
<td>269.18</td>
<td></td>
<td></td>
</tr>
<tr>
<td>05 F5</td>
<td>28.3</td>
<td>150.9 160 170.2 188.8 190.2 193.4 198.8 198.8 210.4 211.5 212</td>
<td>230.39</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>28.6</td>
<td>150 153 159.2 159.2 176.4 176.4 189.1 198.8 208.8 213.5 213.5</td>
<td>230.42</td>
<td>230.42 230.00 230.00±0.71</td>
<td></td>
</tr>
<tr>
<td>08 F8</td>
<td>33.9</td>
<td>209.4 181 251.5 250.5 250.8 250.8 250.8 251.8 252.9 252.9 252.9</td>
<td>294.99</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>33.4</td>
<td>173.9 184 210.2 230.1 245.2 242.6 259.4 234.9 234.9 253.2 253.2</td>
<td>294.31</td>
<td>294.44 294.4±0.45</td>
<td></td>
</tr>
<tr>
<td></td>
<td>33.5</td>
<td>160.9 173 173.2 190.8 210.4 210.4 230.1 237.5 247.2 247.2 247.2</td>
<td>294.03</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09 F9</td>
<td>31.1</td>
<td>180.7 194 201.2 205.2 205.2 212.1 212.1 213.3 213.3 215.5 215.5</td>
<td>224.44</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>30.9</td>
<td>179.8 190 205.5 205.7 210.3 213.1 215 215 215 216.9 224.92</td>
<td>224.36 224.4±0.79</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>31.2</td>
<td>185.1 196 203.3 205.1 210 210 210 211 211 211 211</td>
<td>223.72</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Table 5. Cumulative percentage release of drug from swellable oral thin films of metoclopramide hydrochloride from F1 to F9.

<table>
<thead>
<tr>
<th>Formulation code</th>
<th>0.00</th>
<th>5.00</th>
<th>10.00</th>
<th>15.00</th>
<th>20.00</th>
</tr>
</thead>
<tbody>
<tr>
<td>F1</td>
<td>0.00</td>
<td>10.0</td>
<td>22.4</td>
<td>83.4</td>
<td>102.4</td>
</tr>
<tr>
<td>F2</td>
<td>0.00</td>
<td>17.6</td>
<td>40</td>
<td>79.2</td>
<td>102</td>
</tr>
<tr>
<td>F3</td>
<td>0.00</td>
<td>11</td>
<td>32.2</td>
<td>65.2</td>
<td>100</td>
</tr>
<tr>
<td>F4</td>
<td>0.00</td>
<td>20.6</td>
<td>49.8</td>
<td>71.6</td>
<td>99.6</td>
</tr>
<tr>
<td>F5</td>
<td>0.00</td>
<td>14.2</td>
<td>33.6</td>
<td>63.2</td>
<td>101.6</td>
</tr>
<tr>
<td>F6</td>
<td>0.00</td>
<td>10.2</td>
<td>35.4</td>
<td>63</td>
<td>94.8</td>
</tr>
<tr>
<td>F7</td>
<td>0.00</td>
<td>7.4</td>
<td>22.4</td>
<td>57.8</td>
<td>98.4</td>
</tr>
<tr>
<td>F8</td>
<td>0.00</td>
<td>24</td>
<td>45.6</td>
<td>72.8</td>
<td>103</td>
</tr>
<tr>
<td>F9</td>
<td>0.00</td>
<td>11.6</td>
<td>26.8</td>
<td>67.4</td>
<td>101.2</td>
</tr>
</tbody>
</table>
Effect of glycerin and povidone K 90 on morphological features and peeling effect of film: Glycerin and Povidone K90 were used in varying quantities in the film formulations F1 to F9. F1 to F3 had 0.25 mg/film glycerin and 5 mg, 10 mg, 15 mg of Povidone K90 per film in the drug layer. These films were less glossy in appearance, but were easily peeled from the glass plate. Formulations F4 to F6 had 0.40 mg/film of glycerin and 20 mg, 25 mg, 30 mg of Povidone K90 per film. These films were glossier compared to F1 to F3, peeling of these film formulations were comparatively more difficult. Formulations F7 to F9 had 0.55 mg/film of glycerin and 35 mg, 40 mg, 45 mg of Povidone K90 per film. These films were the most glossy, peeling of these film formulations the most difficult of all.
Figure 8. Comparative % drug content of swellable oral thin film of etoclopramide HCl.

Figure 9. FT-IR spectrum of metoclopramide hydrochloride standard.

Figure 10. FT-IR spectrum of swellable oral thin film of metoclopramide hydrochloride.
Table 6. Various properties of swellable oral thin film of metoclopramide HCl.

<table>
<thead>
<tr>
<th>F code</th>
<th>Mass (mg) ± S.D n=10</th>
<th>Thickness of film (mm) ± S.D (n =10)</th>
<th>Linear expansion co-efficient (L %)</th>
<th>Amount of water absorbed (%)</th>
<th>Drug content (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>F₁</td>
<td>29.44±0.412</td>
<td>97.8±0.919</td>
<td>50.167±0.289</td>
<td>740.8±0.685</td>
<td>100.09±0.893</td>
</tr>
<tr>
<td>F₂</td>
<td>32.80±0.343</td>
<td>120.5±0.527</td>
<td>45.00±0.00</td>
<td>441.5±0.376</td>
<td>99.445±0.608</td>
</tr>
<tr>
<td>F₃</td>
<td>39.09±0.513</td>
<td>183.10±0.738</td>
<td>40.167±0.289</td>
<td>570.6±0.425</td>
<td>99.444±0.881</td>
</tr>
<tr>
<td>F₄</td>
<td>49.47±0.457</td>
<td>180.40±0.516</td>
<td>30.167±0.289</td>
<td>269.4±0.250</td>
<td>100.65±0.817</td>
</tr>
<tr>
<td>F₅</td>
<td>52.58±0.358</td>
<td>180.00±0.816</td>
<td>25.00±0.00</td>
<td>230.00±0.706</td>
<td>100.56±0.817</td>
</tr>
<tr>
<td>F₆</td>
<td>57.370±0.858</td>
<td>210.70±0.823</td>
<td>20.167±0.289</td>
<td>317.4±0.179</td>
<td>100.28±0.584</td>
</tr>
<tr>
<td>F₇</td>
<td>64.465±0.343</td>
<td>238.20±0.919</td>
<td>20.333±0.289</td>
<td>271.6±0.283</td>
<td>99.445±0.608</td>
</tr>
<tr>
<td>F₈</td>
<td>69.940±0.638</td>
<td>256.50±0.707</td>
<td>10.667±0.289</td>
<td>294.4±0.450</td>
<td>101.00±0.739</td>
</tr>
<tr>
<td>F₉</td>
<td>71.150±0.242</td>
<td>269.60±0.843</td>
<td>5.00±0.00</td>
<td>224.4±0.786</td>
<td>98.148±0.835</td>
</tr>
</tbody>
</table>

Trinocular microscopic imaging: Trinocular microscopic imaging was done and encircled drug molecules in povidone K 90 matrix was observed (Figure 11).

Figure 11. Trinocular image of metoclopramide hydrochloride swellable oral thin film (Batch F₁).

Conclusion

Swallowable oral thin films are intended for the application in the oral cavity. These noble dosage forms are promising, especially for use with pediatric and geriatric patients. Metoclopramide hydrochloride is a widely used antiemetic drug. In the present study, a sandwiched swallowable oral thin film was formulated which can be easily swallowed without the need of water. Solvent casting method was successfully used in manufacturing of the film. From the present research, we can conclude that metoclopramide hydrochloride was successfully prepared as swallowable oral thin film using Povidone K90 as the drug carrier and polyvinyl alcohol as the gel-forming polymer. The method of manufacturing was simple, less time consuming and cost effective. However, further studies on formulation optimization, compatibility, stability, palatability, release kinetic studies are needed to confirm the appropriateness of this formulated orally swallowable thin film.

References


Committee for medicinal and products for human use, European medicines agency, EMEA. Reflection paper. 2006. Formulation of choice of the pediatric population, pp. 4-45


